This week, the White House introduced a major effort to make in vitro fertilization (IVF) more affordable and accessible for families throughout the U.S. — potentially marking one of the most significant federal steps toward easing the financial burden of fertility care to date.

Under a new federal partnership with EMD Serono, prices for several leading IVF medications — including Gonal-F, Ovidrel, and Cetrotide — are expected to drop by as much as 73% per cycle once the program launches. These changes are part of a “Most-Favored-Nation” pricing model designed to align U.S. drug prices with the lowest international rates for the same medications. In addition, updated federal guidance will soon allow employers to offer standalone fertility benefits, similar to dental or vision plans, giving more families access to reproductive health coverage through work.

This news comes at a pivotal moment. According to recent SART data, IVF use has climbed rapidly — up 6% in 2022 and over 10% in 2023. Donor egg IVF is also on the rise, driven by an increase in LGBTQ+ family building, age-related fertility challenges, and medical conditions that make conception more difficult. Donor egg cycles now make up nearly 12% of all IVF treatments and boast an impressive 52% national success rate, the highest among fertility options. Meanwhile, the World Health Organization reports that infertility affects 1 in 6 adults worldwide, underscoring a growing global need for accessible reproductive care.

What This Means for Intended Parents

While these developments are promising, they’re not yet active. Here’s what you should know as these initiatives progress toward 2026:

• Currently in treatment: Your existing medication plan remains the same. When the TrumpRx program begins, your care team will help determine eligibility for future discounts.
• Planning a future IVF cycle: You may see lower medication costs starting in 2026 once new pricing becomes available.
• Employer coverage: More workplaces may soon include fertility benefits as part of their insurance offerings.
• Overall outlook: If these initiatives move forward, fertility care could become more financially accessible and inclusive for many families nationwide.

The medication discounts apply to three core IVF drugs that form the foundation of most fertility and egg-freezing protocols.

• Gonal-F (FSH hormone) helps the ovaries produce multiple mature eggs.
• Cetrotide prevents premature ovulation during stimulation.
• Ovidrel triggers final egg maturation and ovulation.

According to EMD Serono, patients could see up to an 84% combined savings when using these medications together, significantly reducing out-of-pocket costs per treatment cycle.

However, these benefits will take time to reach patients. The TrumpRX program, which will distribute the discounted medications, is expected to launch in early 2026, following regulatory approvals and contracting phases. Similarly, employers will need time to design and roll out their new fertility benefit programs. Questions remain around whether these benefits will be pre-tax and how coverage will vary by employer.

For now, families may not experience immediate relief, but the long-term potential is promising. Lower medication costs and expanded insurance options could make IVF more attainable and less financially stressful for countless hopeful parents.

What This Could Mean for the Future of Fertility Care

The cost of fertility treatment remains one of the biggest barriers to parenthood — with medications alone often adding thousands of dollars per cycle. Officials estimate the new pricing model could save patients roughly $2,200 per IVF cycle, marking a meaningful move toward nationwide affordability. While full implementation will take time, these actions suggest growing federal recognition of fertility care as an essential healthcare service.

The effectiveness of these programs depends on execution and reach. This initiative signals progress toward a more inclusive, equitable future in reproductive medicine.

Highlights of the New Fertility Care Plan

Discounted IVF Medications through TrumpRx: Beginning in January 2026, a new federal platform, TrumpRx.gov, is expected to launch, offering reduced pricing on several EMD Serono fertility medications—Gonal-f®, Ovidrel®, and Cetrotide®.

Employer Fertility Benefit Programs: The federal government will begin encouraging employers to add standalone infertility benefits—similar to dental or vision insurance options. While this guidance is optional and not federally funded, it could inspire more employers to expand fertility coverage for their teams.

Expedited FDA Review: The FDA is set to fast-track the approval of EMD Serono’s fertility medication Pergoveris, which may help patients access more advanced treatment options sooner.

How Luxe IVF Supports Intended Parents

At Luxe IVF, we understand the challenges — emotional, financial, and logistical — that come with building a family through assisted reproduction. While national policy changes evolve, our mission remains the same: to make the fertility journey as transparent, supported, and accessible as possible.

Our team works closely with intended parents and egg donors worldwide, offering expert coordination, guidance, and emotional support every step of the way. We’ll continue to monitor these new policy developments and share updates as they become available — ensuring every patient has the information and care they need to move forward with confidence.

Key Takeaways

• Discounts will become available through TrumpRx.gov starting in early 2026.
• Families could save an estimated $2,200 per IVF cycle.
• Discounts will apply only to select EMD Serono medications, which may not be part of every fertility treatment plan.
• EMD Serono to provide discounted pricing on Gonal-F, Ovidrel, and Cetrotide when used together.
• Patients should continue following updates through trusted sources such as Reuters for the latest information.